65.78
+0.7224(+1.11%)
Currency In USD
| Previous Close | 65.06 |
| Open | 66.13 |
| Day High | 66.5 |
| Day Low | 64.89 |
| 52-Week High | 68.73 |
| 52-Week Low | 30.82 |
| Volume | 183,406 |
| Average Volume | 357,455.2 |
| Market Cap | 2.29B |
| PE | -14.75 |
| EPS | -4.46 |
| Moving Average 50 Days | 60.36 |
| Moving Average 200 Days | 54.79 |
| Change | 0.72 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $638.66 as of September 30, 2025 at a share price of $65.782. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $4,011.12 as of September 30, 2025 at a share price of $65.782.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
GlobeNewswire Inc.
5 hours ago
Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IR
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
GlobeNewswire Inc.
Jul 21, 2025 12:00 PM GMT
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
GlobeNewswire Inc.
Jul 14, 2025 12:30 PM GMT
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h